PIK3CA and breast carcinoma: For instance, BEZ235, a dual pan-class I PI3K and mTOR kinase inhibitor, has shown antitumor activity in vitro and in vivo in breast cancer models that harbour PI3KCA mutations [25] or are resistant to anti-HER2 therapies [26].